The Antibody Cocktail, launched in India on Monday for treatment of mild to moderate COVID-19 in patients, is working against the disease, Dr Naresh Trehan said on Wednesday. One of the top doctors in the country, Trehan also said that the Antibody Cocktail, which is a combination of Casirivimab and Imdevimab, is effective against the B.1.617 variant of coronavirus, first …
In a joint statement, the pharma giants said that the second batch of the Antibody Cocktail will be available by mid-June New Delhi: Drug majors Roche India and Cipla on Monday announced launch of Roche’s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. …
Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for …
Indian regulators have given emergency use authorization for an antibody-drug cocktail developed by Roche and Regeneron to treat COVID-19, Roche’s local partner said on Wednesday. The Central Drugs Standards Control Organisation gave Emergency Use Authorisation for its antibody cocktail Casirivimab and Imdevimab in India. The approval of antibody cocktail of Casirivimab and Imdevimab in India was based on the data …
)
)
)